- Home
- WLGS vs SONN Comparison
WLGS vs SONN Comparison
Compare WLGS & SONN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WLGS
- SONN
- Stock Information
- Founded
- WLGS 1981
- SONN N/A
- Country
- WLGS Hong Kong
- SONN United States
- Employees
- WLGS N/A
- SONN N/A
- Industry
- WLGS Engineering & Construction
- SONN Biotechnology: Pharmaceutical Preparations
- Sector
- WLGS Consumer Discretionary
- SONN Health Care
- Exchange
- WLGS Nasdaq
- SONN Nasdaq
- Market Cap
- WLGS 4.4M
- SONN 3.8M
- IPO Year
- WLGS 2023
- SONN N/A
- Fundamental
- Price
- WLGS $0.04
- SONN $9.77
- Analyst Decision
- WLGS
- SONN Strong Buy
- Analyst Count
- WLGS 0
- SONN 1
- Target Price
- WLGS N/A
- SONN $20.00
- AVG Volume (30 Days)
- WLGS 65.2M
- SONN 11.0M
- Earning Date
- WLGS 08-14-2025
- SONN 08-13-2025
- Dividend Yield
- WLGS N/A
- SONN N/A
- EPS Growth
- WLGS N/A
- SONN N/A
- EPS
- WLGS N/A
- SONN N/A
- Revenue
- WLGS $3,951,649.00
- SONN $1,000,000.00
- Revenue This Year
- WLGS N/A
- SONN $5,376.22
- Revenue Next Year
- WLGS N/A
- SONN N/A
- P/E Ratio
- WLGS N/A
- SONN N/A
- Revenue Growth
- WLGS N/A
- SONN 978.39
- 52 Week Low
- WLGS $0.03
- SONN $1.08
- 52 Week High
- WLGS $9.66
- SONN $19.30
- Technical
- Relative Strength Index (RSI)
- WLGS 31.65
- SONN 93.10
- Support Level
- WLGS $0.04
- SONN $4.19
- Resistance Level
- WLGS $0.08
- SONN $19.30
- Average True Range (ATR)
- WLGS 0.01
- SONN 1.74
- MACD
- WLGS 0.01
- SONN 0.76
- Stochastic Oscillator
- WLGS 23.18
- SONN 47.64
About WLGS Wang & Lee Group Inc.
WANG & LEE Group Inc operates as an investment holding company. The firm conducts its primary operations through its indirectly wholly owned subsidiary WANG and LEE CONTRACTING LIMITED. WLHK provides contract engineering, installation, and out-fitting of the following products and services: low voltage electrical systems, mechanical ventilation and air-conditioning systems (MVAC), fire safety systems, water supply and sewage disposal systems, and site project management.
About SONN Sonnet BioTherapeutics Holdings Inc.
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.